CSL Bioplasma product information is available for these countries:
CSL Bioplasma fractionates (manufactures) plasma-derived therapeutics at its unique, purpose-built plasma fractionation facility at Broadmeadows, in Victoria, Australia.More than AUD$500 million has been invested in this facility, to create one of the most sophisticated plasma fractionation facilities in the world. Commissioned in 1994, it is the only commercial scale facility of its type, and was the first commercial plant to use chromatography – a technology that is now in widespread use to fractionate plasma. CSL Bioplasma has more than 50 years experience as a fractionator and innovator in the field of plasma-derived therapeutics, and is chosen by Australia, New Zealand, Hong Kong, Singapore, Malaysia and Taiwan as their national fractionator. CSL Bioplasma, together with CSL Behring’s centres of excellence in plasma-derived therapeutics located in Bern, Switzerland (IVIg and albumin), and Marburg, Germany (clotting factors), now offers healthcare professionals the world’s broadest range of world class plasma-derived therapeutics.